Annibali Gianmarco, Scrocca Innocenzo, Aranzulla Tiziana Claudia, Meliga Emanuele, Maiellaro Francesco, Musumeci Giuseppe
Cardiology Department, Azienda Ospedaliera Ordine Mauriziano Umberto I, 10128 Turin, Italy.
J Clin Med. 2022 Apr 16;11(8):2233. doi: 10.3390/jcm11082233.
Primary percutaneous angioplasty (pPCI), represents the reperfusion strategy of choice for patients with STEMI according to current international guidelines of the European Society of Cardiology. Coronary no-reflow is characterized by angiographic evidence of slow or no anterograde epicardial flow, resulting in inadequate myocardial perfusion in the absence of evidence of mechanical vessel obstruction. No reflow (NR) is related to a functional and structural alteration of the coronary microcirculation and we can list four main pathophysiological mechanisms: distal atherothrombotic embolization, ischemic damage, reperfusion injury, and individual susceptibility to microvascular damage. This review will provide a contemporary overview of the pathogenesis, diagnosis, and treatment of NR.
根据欧洲心脏病学会当前的国际指南,直接经皮冠状动脉介入治疗(pPCI)是ST段抬高型心肌梗死(STEMI)患者的首选再灌注策略。冠状动脉无复流的特征是造影显示心外膜前向血流缓慢或无血流,导致在没有机械性血管阻塞证据的情况下心肌灌注不足。无复流(NR)与冠状动脉微循环的功能和结构改变有关,我们可以列出四种主要的病理生理机制:远端动脉粥样硬化血栓栓塞、缺血损伤、再灌注损伤以及个体对微血管损伤的易感性。本综述将对无复流的发病机制、诊断和治疗进行当代概述。